ADAMTS‐13 and Von Willebrand Factor Predict Venous Thromboembolism in Patients With Cancer

touch_app Click to see the full documentopen_in_new
Authors: Harry Roger BüllerPieter Willem KamphuisenMarcello Di NisioDavid HajageAgnès VeyradierIsabelle MahéAlain StepanianAnkie KleinjanL SalomonMarion Pépin
Year: 2016
Times cited: 33

Key People For Willebrand Factor

Top KOLs in the world
Zaverio M Ruggeri
willebrand factor platelet adhesion thrombus formation
J Evan Sadler
willebrand factor thrombotic thrombocytopenic plasma exchange
Pier Mannuccio Mannuccio Mannucci
willebrand factor venous thromboembolism myocardial infarction
Dominique Meyer
willebrand factor platelet adhesion type iia
Jan J Sixma
platelet adhesion willebrand factor flow conditions
Denisa D Wagner
willebrand factor endothelial cells deep vein thrombosis

ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer


ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.

BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which plays a role in the development of cancer and in VTE.

OBJECTIVES: The aim of this study was to search for an association between the levels of VWF and ADAMTS-13 and VTE in patients with cancer and to compare current scoring systems for prediction of VTE before and after addition of these parameters.

PATIENTS/METHODS: In a case-control study, in which patients with recently diagnosed cancer were followed-up for 6 months, we compared 20 patients who developed VTE (cases) and 140 patients with cancer without VTE (controls), matched for sex, age, and type and stage of cancer. We measured VWF, ADAMTS-13 (activity and antigen), P-selectin, D-dimer and F1 + 2 levels at baseline, and calculated both the Khorana score and the Khorana score expanded after addition of P-selectin and D-dimer levels.

RESULTS: VWF levels were significantly higher in cases when compared with controls (326 ± 185% vs. 242 ± 158%) and correlated with advanced stage of cancer: localized, 185 [142; 222]; locally advanced, 240 [146; 257]; metastatic, 267 [153; 324] (mean [interquartile range]). The addition of two biomarkers, ADAMTS-13 activity and F1 + 2 levels, to the Khorana score improved receiver operating curves.

CONCLUSIONS: von Willebrand factor and ADAMTS-13 are associated with the occurrence of VTE in patients with cancer. Moreover, addition of ADAMTS-13 and F1 + 2 levels to the Khorana score considerably increases the predictive value for VTE.

to see all concepts, it's free!

FREE Custom List